<DOC>
	<DOCNO>NCT03061006</DOCNO>
	<brief_summary>Patients screen Intermountain Medical Center Intermountain-affiliated anticoagulation clinic Salt Lake City region . Patients non-valvular atrial fibrillation consider study . After write informed consent obtain , subject meet eligibility criterion randomize 1:1 2 treatment arm : Group 1 : Dabigatran etexilate ( 150 mg BID CrCL &gt; 30 mL/min , 75 mg BID CrCL &gt; 15 30 mL/min per USPI ; Group 2 : Warfarin ( Dose-adjusted ( INR 2.0 - 3.0 ) . Assessment kidney function every 6 month do Group 1 . Standard warfarin follow-up education , base upon system criterion , do Group 2 . All subject follow 24 month , assess 1-week , 3- , 6- , 12- , 18- 24-months post-anticoagulation visit well visit deem necessary clinical care . All subject undergo protocol-specified laboratory test complete 6 standard , validated questionnaire follow-up visit follow week 1 visit , except 3-month visit one questionnaire administer . To determine brain volume characteristic change representative micro-bleeding , first 10 subject treatment group willing able undergo procedure participate MRI sub-study . The cranial MRI do baseline 24-months post-anticoagulation sub-group .</brief_summary>
	<brief_title>Impact Anticoagulation Therapy Cognitive Decline Dementia Patients With Non-Valvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Male female &gt; 65 year age . 2 . Nonvalvular atrial fibrillation document electrocardiogram , ambulatory event monitor , telemetry within 12 month enrollment . 3 . Moderate risk thromboembolism base upon CHADS score CHADS2 Vasc score â‰¥2 . 4 . Ability complete minimental status evaluation . 5 . Ability independently comprehend complete quality life dementia questionnaire . 6 . Ability provide inform consent study participation . 7 . Willing able comply prescribe followup test schedule evaluation . 1 . Inability take anticoagulant due know perceive bleed risk . 2 . Known coagulopathy may impact choice , duration , efficacy safety anticoagulation therapy . 3 . Atrial Fibrillation set valvular heart disease . Valvular heart disease define surgical valve , mitral stenosis , moderatesevere valvular heart disease . 4 . Severe renal dysfunction , define creatinine clearance rate &lt; 15 mL/min ( document within last 3 month ) . 5 . History form dementia . 6 . A life expectancy le 24 month . 7 . Inability comply followup schedule . 8 . Current participation clinical investigation include active pharmacologic treatment arm . 9 . An upper age limit use participation inclusion criterion meet . 10 . Participation clinical trial involve investigational market product within 30 day prior entry study . 11 . Other condition opinion Principal Investigator ( ) may increase risk subject and/or compromise quality clinical trial . 12 . Concurrent pharmacologic treatment require treat condition longterm concurrent use dabigatran etexilate contraindicate . 13 . Treatment anticoagulant drug stroke prevention 30 day . Aspirin P2Y12 inhibitor ( e.g . clopidogrel ( Plavix ) , prasugrel ( Effient ) ) consider anticoagulant drug . If subject receive anticoagulant drug stroke prevention le 30 day , Principal Investigator ( ) CoInvestigator decide whether subject eligible study 14 . The Principal Investigator ( ) determine ( ) subject eligible participation research study .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>